Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans
April 27, 2021 - Biodesix Announces Presentation on SARS-CoV-2 Neutralizing Antibody Testing for Individual Vaccine Response and Commercial Launch Plans.
February 16, 2021 - Biodesix, Inc. today announced that the company has partnered with Chicago Public Schools (CPS) to provide antigen and Droplet Digital PCR (ddPCR)™ testing for Chicago Public School teachers and staff.
January 6, 2021 - Purdue University is partnering with a Colorado company led by a Purdue alum to offer rapid antigen COVID-19 testing for undergraduate, graduate and professional students taking classes on the West Lafayette campus who will be living off campus (not in the residence halls or in Fraternity, Sorority and Cooperative Life housing) during the spring 2021 semester.
September 30, 2020 - The Big Ten Conference has entered into strategic partnerships with Biodesix, Inc., a leading diagnostic company with a focus on lung disease, and Quidel Corporation, the manufacturer of the FDA-authorized SOFIA 2 SARS rapid antigen test.
August 12, 2020 - Biodesix, Inc. today announced plans to provide COVID-19 ddPCR diagnostic testing for Colorado State University (CSU) as students return to campus for the fall term, which begins August 24.
July 13, 2020 - Major League Lacrosse (MLL) today announced a partnership with Biodesix, Inc., whereby Biodesix will be the exclusive provider of COVID-19 testing for the upcoming 2020 MLL season.
June 8, 2020 - Biodesix has launched the Biodesix WorkSafe™ Program, a customized return to work service for employers. Learn more about the testing program.
May 20, 2020 - The Biodesix SARS-CoV-2 ddPCR™ Test detects COVID-19 with greater sensitivity than other available tests, and is now accessible by appointment at drive-up locations in Boulder and Erie.
May 19, 2020 - Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it has collaborated with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to launch a blood-based immunoassay-based test that identifies antibodies to SARS-CoV-2, the virus that causes COVID-19.
April 8, 2020 - Biodesix, Inc., a leading diagnostic company in lung disease, today announced that it began SARS-CoV-2 Droplet Digital PCR (ddPCR) testing for the virus that causes COVID-19 and will immediately submit for Emergency Use Authorization from the Food and Drug Administration.
March 20, 2020 - Biodesix, Inc., a leading diagnostic company in lung disease, today announced a partnership with Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb) to bring a COVID-19 Droplet Digital PCR (ddPCR) test to the FDA for an Emergency Use Authorization (EUA) approval to support the escalating need for testing in the U.S.
